Clinical efficacy of mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis / 中国基层医药

ABSTRACT

Objective To investigate the clinical efficacy and safety of mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis.Methods From January 2016 to December 2016, a total of 120 patients with colitis gravis in the Second Hospital of Qinhuangdao were selected in the research .According to different treatment methods,the patients were divided into observation group and control group ,with 60 cases in each group.The control group was given mesalazine , and the observation group was given mesalazine combined with Clostridium butyricum tablets.All the patients were treated for 2 months.The changes of cytokine levels and C -reactive protein were observed.The therapeutic effects and adverse drug reactions were compared between the two groups . Results The total effective rate of the observation group was significantly higher than that in the control group (91.66%vs.78.33%),and there was statistically significant difference between the two groups ( χ2＝4.183,P＝0.041).The level of IL-10 in the observation group was significantly higher than that in the control group [(110.05 ± 2.61)pg/L vs.(98.35 ±2.42)pg/L,t＝25.462,P＜0.05].The IL-18 level in the observation group was significantly lower than that in the control group [(97.74 ±2.82) pg/L vs.(120.86 ±3.21) pg/L,t＝41.914,P＜0.05].The level of C-reactive protein in the observation group was lower than that in the control group [(8.02 ±1.97) mg/L vs.(6.33 ±3.82)mg/L,t＝14.976,P＜0.05].The incidence rate of adverse reactions of the observation group was significantly lower than that of the control group ( 5.00% vs.25.00%, χ2＝9.412, P ＝0.002 ).Conclusion Mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis has obvious curative effect , and can effectively improve the levels of cytokines and C -reactive protein and with high safety.